Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Northeast Pharma of China filed for a $370 million...
The ChinaBio® Investor Forum–Jinan chose...
Shionogi will pay $185 million to obtain a controlling...
China’s central government spent $38.4 billion on...
The SFDA released a summary of its 2010 decisions,...
China National Biotechnology Group (CNBG) will raise as...
Shanghai Duyiwei Biotechnology, a subsidiary of Gansu...
WuXi AppTec and MedImmune, an AstraZeneca subsidiary,...
PerkinElmer paid $38 million to buy Shanghai Haoyuan...
In 2012, China’s life science’s VC...
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
